IMMUNOHISTOCHEMISTRY, CD 138

The Immunohistochemistry (IHC) – CD138 test is a specialized diagnostic test used to detect CD138 (Syndecan-1) protein expression in tissue samples. CD138 is a cell surface protein highly expressed on plasma cells, making it an important marker in diagnosing plasma cell-related disorders and certain epithelial tumors.

This test is widely used in hematopathology for identifying and evaluating plasma cell neoplasms, especially multiple myeloma and plasmacytoma. Detecting CD138 helps pathologists confirm the presence, number, and distribution of abnormal plasma cells within tissue or bone marrow samples.

The CD138 marker is especially useful in diagnosing:

• Multiple myeloma
• Plasmacytoma
• Plasma cell dyscrasias
• Certain lymphoid malignancies
• Selected epithelial cancers and metastatic lesions

The test helps distinguish plasma cell disorders from other hematologic conditions and supports accurate disease classification.

The CD138 IHC test is commonly performed along with markers such as Kappa, Lambda, CD38, CD56, Ki-67, and MUM1 for comprehensive plasma cell analysis and precise diagnosis.

Benefits of the Test

The CD138 test offers several important clinical benefits:

• Detects plasma cells accurately
• Helps diagnose multiple myeloma and plasmacytoma
• Supports plasma cell disorder classification
• Assists in evaluating disease extent
• Improves diagnostic precision
• Helps guide treatment planning

This test is essential for accurate plasma cell pathology evaluation.

Why Doctors Recommend This Test

Doctors recommend the CD138 test when plasma cell abnormalities are suspected.

It is commonly advised for:

• Suspected multiple myeloma diagnosis
• Bone marrow plasma cell evaluation
• Plasmacytoma confirmation
• Plasma cell disorder classification
• Advanced hematopathology assessment

The results help hematologists and oncologists establish diagnosis and determine appropriate treatment strategies.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected bone marrow biopsy or tissue specimens.

Normal Reporting Time

The usual turnaround time for the CD138 IHC test is 2 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with suspected multiple myeloma
• Individuals with plasma cell abnormalities
• Patients requiring bone marrow plasma cell analysis
• Cases needing plasma cell disorder classification
• Oncology patients requiring precise diagnosis

The IHC CD138 test is an essential diagnostic tool in hematopathology. It supports accurate plasma cell identification, improves diagnostic confidence, and helps guide personalized treatment planning for better patient outcomes.